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Background: Virus neutralizing antibodies against respiratory syncytial virus (RSV) are considered important
correlates of protection for vaccine evaluation. The established plaque reduction assay is time consuming, labor
intensive and highly variable.
Methods: Here, a neutralization assay based on a modified RSV strain expressing the green fluorescent protein in
combination with automated detection and quantification of plaques is described.
Results: The fluorescence plaque reduction assay in microplate format requires only two days to complete and is
simple and reproducible. A good correlation between visual and automated counting methods to determine RSV
neutralizing serum antibody titers was observed.
Conclusions: The developed virus neutralization assay is suitable for high-throughput testing and can be used for
both animal studies and (large scale) vaccine clinical trials.
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Human Respiratory Syncytial virus (RSV) is a non-
segmented, negative-strand RNA Virus and is a member
of the Paramyxoviridae. RSV is the most common cause
of lower respiratory tract infections in infants and eld-
erly [1-3]. The majority of infected subjects develop
upper respiratory tract infection, but in severe cases
RSV infection can result in bronchiolitis, pneumonia
and mortality. RSV is increasingly being recognized as a
significant cause of morbidity and mortality in the eld-
erly, with an impact approaching that of non-pandemic
influenza [4]. The high disease burden indicates an ur-
gent need for an efficacious vaccine against RSV, how-
ever despite numerous approaches aimed at its* Correspondence: mwidjojo@its.jnj.com
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distribution, and reproduction in any mediumdevelopment there is currently no licensed vaccine avail-
able. Major obstacles include the legacy of RSV vaccine
enhanced disease and early age of RSV infection. Prom-
ising vaccine candidates currently in preclinical or clin-
ical testing include live- attenuated recombinant RSV,
chimeric viruses and replication-defective vectors [5].
Accordingly, there is need for reliable and high-
throughput tests to determine the immunogenicity of vac-
cine candidates in both animal models and large-scale
clinical trials. While there are many methods providing in-
formation on different aspects of the immune response,
the neutralization assay for RSV antibodies remains the
most reliable correlate of protection [6,7]. The fact that
currently the only available prophylactic agent against
RSV infection is a virus neutralizing monoclonal antibody
preparation underscores the importance of virus neutraliz-
ing antibodies in protection from severe disease [8].
The power of the neutralization assay lies in its ability to
detect biologically active antibodies. In the conventionald Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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plaques are counted manually, often with the aid of a
microscope. This is a laborious and time consuming pro-
cedure, while operator bias makes it less suitable for clin-
ical trials that involve testing large numbers of samples in
multiple centres. Therefore, improvement of the assay is
required to optimize inter-lab testing and throughput.
Reports on optimization of the virus neutralization (VN)
assay include visualization of plaques by biochemical
staining of monolayers [9], but still this requires manual
counting of plaques. Another study reports the use of an
automated plaque counting method that still requires
immunostaining [10]. None of these approaches circum-
vent all constraints of the traditional assay format.
Recent reports have shown that virus constructs con-
taining the (E)GFP gene can be used for more easy and
quick determination of virus neutralizing activity [11-13].
This finding enables the development of an assay system



































Figure 1 A) Schematic diagram of constructed recombinant RSV (rRSV-
(E7-rRSV-X) position in the virus genome and the positions of the restri
Blue: RSV gene; green: EGFP gene. B) Replication kinetics of recombinant RSV
cells. Cells were infected at a multiplicity of infection (MOI) of 0.1 with the rRS
and virus titers were determined. Closed lines represent growth on Vero cellsand operator dependent, thereby making the assay more
suitable for standardization and high throughput pur-
poses. Importantly, this would also facilitate validation of
the assay according to ICH guidelines, thus enabling its
use in multicenter clinical trials. In this report, the deve-
lopment of such an assay for detection of RSV neutralizing
antibodies is described. The assay design is based on a
recombinant RSV construct expressing EGFP from the
viral genome in combination with automated fluorescent
plaque counting. Our results show good correlation
between visual and automated counting methods to deter-
mine RSV neutralizing serum antibody titers.
Results
Replication of recombinant RSV harbouring the EGPF
gene
Using reverse genetics, the EGFP gene was inserted
either at the 3’ proximal site (E1-rRSV-X) or between












X) expressing EGFP gene in the first (E1-rRSV-X) and the seventh
ction enzymes in the RSV-X genome used for insertion of EGFP.
viruses E1-rRSV-X, E7-rRSV-X and the parental rRSV-X in Vero and Hep-2
Vs. At the indicated time points, cells and supernatants were collected
; dashed lines represent growth on Hep-2 cells.
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readily detectable using a fluorescence microscope (data
not shown). The growth kinetics of the recombinant
viruses was compared with their parental recombinant
wild-type virus (rRSV-X). For this purpose, Vero and
Hep-2 cells were infected with a multiplicity of infection
(MOI) of 0.1 (Figure 1B). Growth of E7-rRSV-X on
either Vero or Hep-2 cells was indistinguishable from
the parental rRSV-X strain, reaching peak titers of 107
TCID50.ml
-1 at 72 hrs post infection of Vero cells. Con-
struct E1-rRSV-X was attenuated compared to rRSV-X
and E7-rRSV-X. Therefore, E7-rRSV-X was selected for
use in development of the fluorescent plaque assay.
Virus neutralization (VN) assay using E7-rRSV
First, an optimal virus inoculum that resulted in clear and
distinct fluorescent virus plaque formation after one to
three days of incubation was determined. The established
optimum of 30 to 300 PFU (data not shown) is in the
same order of magnitude as used in the conventional RSV
assay as well as in other conventional virus neutralization
assays. An inoculum of 115 PFU was used as standard for
all further assays. Analysis of EGFP expression over time
showed that plaques of E7-rRSV-X infected cells are
already visible after 27 hours (Figure 2). However, their
size was small and the relatively low fluorescence intensity







Figure 2 Fluorescent images of Vero cells infected with E7-rRSV-X ov
produced by RSV expressing EGFP. At the indicated time points, plaques w
reader, manual counted (upper panel) and counted using the AID EliSpot S
panel) or “tiny” (lower panel). Each yellow ‘x’ represents one plaque counteto allow for accurate automated plaque counting. At 72
hrs post infection large differences in plaque size were
observed, complicating the establishment of fixed settings
on the equipment required for automated plaque count-
ing. An incubation time of 48 hrs proved to be optimal for
data acquisition and quantification of plaques; at this time
point small, individual and bright fluorescent plaques with
little variation in size were observed. Next, the correlation
was assessed between automated counting of fluorescent
plaques and manual counting of the same plaques immu-
nostained (Figure 3). A high correlation was observed
when comparing plaques against the rE7-rRSV virus by
both automated fluorescent and manual immunostained
plaque counting (R=0.98). Serum neutralizing antibodies
titers tend to be higher when assayed in the presence of
guinea pig complement [14]. Therefore, the effect of com-
plement on the fluorescent virus neutralization assay was
assessed using RSV specific human reference sera obtained
through the NIH Biodefense and Emerging Infections Re-
search Resources. Figure 4 shows the effect of guinea pig
complement on the plaque reduction capacity of the
serum. The obtained serum neutralizing antibody titers
for the low, medium and high human reference serum
pools were 11.4, 12.3 and 13.0 log2 respectively in the
presence of complement and 9.1, 9.6 and 11.3 log2 in the
absence of complement. These data correspond well to
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Figure 3 Correlation of automated and conventional plaque
counting. Scatter plots of counted plaques by the automatic
counting of fluorescent plaques (X-axis) and manual counting of the
same plaque immunostained (Y-axis). Plaques were counted 48 hrs























































Figure 4 Sample graph of neutralization assay results with
human reference sera. Virus neutralizing graphs by polyclonal anti-
human reference sera (high, medium and low control) [15] obtained
through the NIH Biodefense and Emerging Infections Research
Resources Repository, NIAID, NIH in the absence (A) or presence (B)
of 10% guinea pig serum. As negative control, control serum from
naive cotton rats was included because of the lack of availability of
negative human reference serum. Plaque reduction titers were
calculated by regression analysis of the inverse dilution of serum
that provided a 60% plaque reduction titer compared to control
wells in the absence of serum. Results are means ± SD (triplicate).
Settings of fluorescence reader are as described for Figure 3.
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in the presence of complement, its addition also decreased
the discriminative power of the assay as it reduced differ-
ences in virus neutralizing titers between control and
reference sera. In addition, complement seemed to inhibit
RSV replication in this infection system, as it required a
two-fold higher input of virus to yield similar plaque
counts. Moreover, the presence of complement increased
inter-assay variation (data not shown). No effect on virus
neutralizing titers was observed when the initial RSV in-
put was either increased or decreased a two-fold (data not
shown).
Next, virus neutralization using conventional, manual
counting of virus plaques using the parental rRSV con-
struct was compared with automated fluorescent plaque
reduction quantification of rE7-rRSV, also to determine
the influence of EGFP insertion into the viral genome
(Figure 5A). There was a good agreement between the
titers obtained by both assays (R= 0.88). Finally, we
wanted to determine if the automated fluorescent virus
plaque reduction assay is appropriate for use in im-
munogenicity studies in both cotton rat and mouse
models of RSV infection. To this aim, virus neutralizing
antibody titers of cotton rat and mouse sera were deter-
mined by the newly developed plaque reduction assay, in
the absence of complement (Figure 5B). Pre-immune
sera from both cotton rats and mice were negative while
infection with a recombinant RSV vaccine candidate
(rRSVΔG) [16] resulted in high virus neutralizing anti-
body titers with low variation between animals within a
group. For comparison, the serum neutralizing antibody
titers obtained for the human reference serum pools are
included. These results suggest that the fluorescent
plaque reduction setup is such that the assay can be per-
formed independent of the host of the serum.
Discussion
We describe the development of a simple and rapid
micro neutralization assay for RSV based on a recom-
binant RSV construct expressing the EGFP protein. To
this aim, we generated two recombinant RSV viruses:
one harbouring EFGP at the 3’ proximal position (E1-
rRSV-X) and one harbouring EGFP between the SH and
G gene (E7-rRSV-X). Both recombinant RSV clones were
constructed with an EGPF gene flanked by RSV gene
start and stop signals, ensuring the expression of EGFP
in virus infected cells. E7-rRSV-X was selected to further
develop the neutralization assay since growth properties
of this virus on Vero cells were indistinguishable from
the parental rRSV-X virus, while E1-rRSV-X was shown
to be attenuated. This suggests that positioning the
EGFP gene at the 3’ end of the viral genome, i.e. before
the first gene, most likely negatively affects transcription
and, by extension, virus growth, a phenomenon that has










































Figure 5 Fluorescent virus neutralizing antibody plaque titers.
A) Scatter plots of virus neutralization (VN) titers obtained by
automatically counted plaques of fluorescence E7-rRSV versus
manually coloured and counted plaque reduction of the parental
rRSV. B) Serum antibody neutralization titers of cotton rat, mouse
and human serum samples obtained with the fluorescent virus
neutralizing antibody assay. Serum neutralizing titers from different
experiments are depicted. Animals were immunized with RSV
vaccine candidates [16]. Pre-immune serum was obtained at day 0
(black bars) and were at the lower limit of detection. Mice were
immunized at day 0 and day 28 with 10^6 RSV- ΔG and serum was
obtained at day 28 (light gray) and at day 51 (gray) (n=6 per group).
Cotton rats were immunized at day 0, day 14 and day 28 with 10^5
RSV-ΔG and serum was obtained at day 28 (light gray) and at day
51 (gray) (n=5 per group). As reference, serum from animals
immunized with formalin-inactivated RSV (white) are included (n=5
per group). The human reference human sera: high (green), medium
(blue) and low (orange) were included as standards [15]. Error bars
indicate standard deviation.
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assay, virus neutralization titers can be determined
within 2 days of incubation without requiring fixation,
staining and manual counting of plaques. The results
showed a strong correlation between automated EFGP
and manual counting of immunostained plaques for the
detection of RSV neutralizing antibody titers.
Serum neutralizing antibody titers to respiratory syncyt-
ial virus (RSV) are higher when assayed in the presence ofguinea pig complement [14,15]. In the current assay, the
addition of complement also resulted in increased virus
neutralizing titers compared to incubation without com-
plement. However, the observation that the amount of
virus needed to obtain similar plaque counts in the pres-
ence of complement suggest a more complex, possibly
confounding influence of complement on the outcome of
the virus neutralization assay. While apparently improving
the sensitivity of the assay, the opposite may be happening
simultaneously through a direct inhibitory effect of com-
plement, as suggested by the need for higher MOI levels
in the test. By directly eliminating a portion of the input
virus, thereby decreasing the number of targets for VN
antibodies, complement may actually decrease the sensi-
tivity of the assay. Therefore we chose to omit the use of
complement in our neutralization assay. These findings
are in agreement with Yoder et al. [14], who reported that
addition of complement did not enhance the ability to de-
tect increased antibody titers after natural infection in
humans and have not found evidence to support its use in
the assay. As these authors, we believe that the addition of
complement introduces an additional, possibly confound-
ing and variable in the performance of the test and we
would advocate that RSV neutralization assays be carried
out without complement, in order to provide a more stan-
dardized and robust assay.
The main advantage of the currently developed
method is that the most time consuming, labour inten-
sive parts of the RSV neutralization assay (i.e. fixation,
staining and plaque counting) are replaced by computer-
ized image scanning and analysis. These features result
in a faster and more efficient assay and ensure less sub-
jective results through the exclusion of operator bias.
Another advantage of the automated counting system is
that it is capable of detecting and differentiating plaques
of different morphology. This feature could be used to
detect serum neutralizing antibodies against other
plaque forming viruses, although this requires recombin-
ant viruses harbouring EGFP. In addition, the fluores-
cence ELISPOT reader can also be used to detect virus
infected cells by staining with fluorescently labelled anti-
bodies as an alternative for the classical plaque forming
unit (PFU) assay. In fact, we have developed such a
fluorescent plaque forming assay for quantification of
RSV that correlates well with the classical PFU assay
(data not shown).
Using the fluorescence ELISPOT reader, a plate can be
processed within 5 min, including reading, counting and
analysis. Robotic automation of plate loading could be
introduced for high throughput purposes. These assets
would render the fluorescent neutralization assay a valu-
able tool for analysis of humoral immune responses in
vaccine studies and for serological studies in naturally
infected hosts. Taken together, our virus neutralization
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described micro neutralization assays [9,10] which still
require either manual plaque counting or immunostain-
ing. Recently, a flow cytometry-based assay to assess
RSV-specific neutralizing has been described [20]. As
our method, this method is based on the expression of
EGPF by the viral genome and can be performed within
two days. However this assay requires manual treat-
ments prior to analysis while our fluorescence-based
plaque reduction assay can be measured directly.
Conclusions
We have used a recombinant RSV virus expressing
EGPF to develop a virus neutralization assay; this elimi-
nates the time consuming fixation and staining steps as
well as manual plaque counting. This fluorescence
plaque reduction assay in microplate format requires
only two days to complete and is simple, reproducible
and suitable for high-throughput analyses. The devel-
oped virus neutralization assay can be used for the ana-
lysis of sera from both animal studies and (large scale)
vaccine clinical trials. Furthermore, our data indicate
that the fluorescent plaque reduction assay can be uti-
lized to measure neutralizing antibody titers against a
broad range of plaque-forming viruses.
Methods
Viruses, cells and serum
Vero cells (CCL-8, American Type Culture Collection
(ATCC)) were cultured (37°C, 5% CO2) in M199 medium
(Invitrogen) supplemented with heat-inactivated 5% foetal
bovine serum (FBS, Hyclone) and PSG (100 units of peni-
cillin, 10 μg of streptomycin and 292 μg of L-glutamine/
ml, Invitrogen). Hep-2 (CCL-23, ATCC) were cultured in
DMEM medium (Invitrogen) with 10% FBS and PSG.
The clinical isolate RSV-X [Genbank FJ948820], a RSV
sero group A strain, was used as the basis to create re-
combinant RSV by reverse genetics [16]. RSV specific
human reference sera was obtained through the NIH
Biodefense and Emerging Infections Research Resources
Repository, NIAID, NIH: polyclonal anti-human Respira-
tory Syncytial Virus (antiserum, human), medium control,
NR-4022; polyclonal anti-human Respiratory Syncytial
Virus (antiserum, human), high control, NR-4021 and
polyclonal anti-human Respiratory Syncytial Virus (anti-
serum, human), NR-4020 designated as low control.
Mouse and cotton rat serum samples were derived from
immunization experiments with RSV vaccine candidates
performed at the RIVM.
Construction of RSV plasmids expressing the EFGP gene
The plasmid containing the complete antigenomic se-
quence (rRSV-X) of the clinical isolate RSV-X [Genbank
FJ948820] [16] was used as basis to construct EGFP-rRSV-X. First, a full-length rRSV cDNA clone with EGPF
at position 7 of the viral genome was constructed. The
EGFP gene was amplified by PCR from the pEGFP plas-
mid (Clonetech) during which gene start and stop sig-
nals of RSV G, both preceded by BsiW I were
introduced. Subsequently, the EGFP amplicon was
digested with BsiW I, and cloned into the BsiW I site of
the RSV cDNA vector (n4667-4672). The resulting plas-
mid was designated E7-rRSV-X.
Second, a full-length rRSV cDNA vector with EGPF at
a natural occurring BstX I site (n35-46) in the leader re-
gion before the first gene of the viral genome was con-
structed. To this end, the EGFP gene was amplified from
pEGFP flanked by the gene start signal of RSV G and
the gene stop signal of N, each preceded by BstX I. This
amplification product was cloned into a subclone har-
bouring the RSV leader sequence along with the NS1,
NS2 and N gene using BstX I. Subsequently, the RSV se-
quence with the EGFP gene of the newly constructed
subclone then was swapped into the full length rRSV
cDNA plasmid using the Kpn I and Xma I restriction
sites. This plasmid was designated E1-rRSV-X.
Recovery of recombinant viruses
Recovery of recombinant RSV harbouring the EGPF
gene was performed as described before [16]. MVA-T7
infected Hep-2 cells were transfected using lipofecta-
mine 2000 with 1.6 μg of the recombinant full length
plasmids and 1.6 μg pcDNA6-A2-N, 1.2 μg pcDNA3-
A2-P, 0.4 μg pcDNA6-A2-L, and 0.8 μg pcDNA6-A2-
M2. After 3 days at 32°C, cells were scraped and used to
infect fresh cultures of Vero cells grown in DMEM + 1%
FCS + PSG. Recovered virus was propagated 4 to 5 times
in Vero cells to obtain high virus titer stocks.
Fluorescence-based plaque reduction assay
Two-fold serial dilutions starting at 1:10 of serum were
prepared in virus diluent (DMEM supplemented with
1% FCS and PSG). Serum was first incubated for 30 min
at 56°C, and then serum dilutions were mixed with an
equal volume of virus (115 plaques/well) and incubated
for 1 hr at 37°C. If sera were tested in the presence of
10% guinea pig complement (Cederlane Laboratories),
this was added to the serum prior to the addition of
virus. Vero cell monolayers, prepared in 96-well plates,
were infected by spin inoculation with 50 μl/well (in
triplicate) of the serum/virus mixture. After centrifuga-
tion for 1 h at 700xg and additional 1 hr incubation at
37°C, supernatant was removed and cells were overlaid
with 1.0% methyl cellulose in DMEM supplemented
with 1% FCS and PSG. Hereafter, the microtiter plates
were incubated at 37°C and 5% CO2. At the indicated
time points, plaques were detected in a fluorescence Eli-
spot reader (AID iSpot FluoroSpot Reader System -
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using the AID EliSpot Software 'algorithm C' with em-
phasis settings were set on ”tiny or were set on “big”.
Plaque reduction titers were calculated by regression
analysis of the inverse dilution of serum that provided a
60% plaque reduction titer compared to control wells
incubated without serum.
Immunostaining of plaques
Vero cells were infected with the serum/virus mixture as
described above. After incubation for two days at 37°C,
the cells were immunostained. To this aim, the overlay
was first removed and the cells were fixed with 80% acet-
one for 30 minutes at room temperature. After incubation
with monoclonal L9 anti-RSV G [21] followed by goat
anti-mouse-IgG-PO (Invitrogen), plaques were visualized
using the True Blue TMB peroxidase substrate (KPL).
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